Asset
SV-BR-1-GM
BriaCell Therapeutics Corp. Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03328026 | phase1_2 | completed | 2018-03-16 | 2026-03-24 | BriaCell Therapeutics Corporation | Combination Study of SV-BR-1-GM With Retifanlimab |
| NCT03066947 | phase1_2 | completed | 2017-05-05 | 2018-11-22 | BriaCell Therapeutics Corporation | SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer |
| NCT06072612 | phase3 | recruiting | 2023-12-05 | 2027-12-01 | BriaCell Therapeutics Corporation | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
FDA applications (0)
This company has no applications containing this asset.